WHO ICTRP trial
A single-center, non-randomized controlled study of the efficacy and safety of…
ChiCTR2600115942 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2600115942 |
|---|---|
| Public title | A single-center, non-randomized controlled study of the efficacy and safety of QL1706 combined with chemotherapy versus chemotherapy alone in the first-line treatment of recurrent/metastatic endometrial cancer |
| Scientific title | A single-center, non-randomized controlled study of the efficacy and safety of QL1706 combined with chemotherapy versus chemotherapy alone in the first-line treatment of recurrent/metastatic endometrial cancer |
| Primary sponsor | Nantong Cancer Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Endometrial cancer |
| Interventions | Group A( QL1706 + carboplatin + paclitaxel):Paclitaxel 135~175 mg/m^2, intravenous infusion, at least 3 hours; Carboplatin AUC 4~5, intravenous infusion, at least 1 hour; QL1706 5 mg/kg, 30~60 minute intravenous infusion, combined with… |
| Registration date | Jan 4, 2026 |
| Target size | Group A( QL1706 + carboplatin + paclitaxel):20;Group B (carboplatin +… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: